Banking on mRNA: engineered platelets

candidates for allogeneic transplant.Here, however, is an opportunity.Many of these responders, such as those with NPM1 mutations, will have very durable responses, potentially equaling or even outdoing the benefits of transplant.Measurable residual disease (MRD) could be used as a means to sort out those who might benefit from transplant.Currently this is routinely available for NPM1-mutated AML, 11 but this highlights the importance of developing and implementing MRD detection methods for a broader array of driver mutations.With these important findings emerging from Viale-A and other studies, and with this reshuffling of risk groups, we have a clearer picture of where we are and a better idea of where we need to go to advance the field of AML therapy.